The Department for Business, Energy and Industrial Strategy (BEIS): Services Agreement for the production of fill finished vaccines for COVID-19 and therapeutics for use in the UK health system

UK-London: Pharmaceutical products.

Section I: Contracting Authority

   I.1) Name, Addresses and Contact Point(s):
       The Department for Business, Energy and Industrial Strategy (BEIS)
       1 Victoria Street, London, SW1H 0ET, United Kingdom
       Tel. +44 3000682861, Email: alessandra.arceiro@beis.gov.uk
       Contact: Alessandra Arceiro
       Main Address: https://www.gov.uk/government/organisations/department-for-business-energy-and-industrial-strategy
       NUTS Code: UK

   I.2) Joint procurement:
      The contract involves joint procurement: No          
      In the case of joint procurement involving different countries, state applicable national procurement law: Not Provided
      The contract is awarded by a central purchasing body: No

   I.4)Type of the contracting authority:
      Ministry or any other national or federal authority, including their regional or local subdivisions

   I.5) Main activity:
      General public services

Section II: Object Of The Contract

   II.1) Scope of the procurement

      II.1.1) Title: Services Agreement for the production of fill finished vaccines for COVID-19 and therapeutics for use in the UK health system            
      Reference number: 2526/07/2020

      II.1.2) Main CPV code:
         33600000 - Pharmaceutical products.


      II.1.3) Type of contract: SUPPLIES

      II.1.4) Short description: The reservation of fill & finish manufacturing capacity at C P Pharmaceutical’s Wrexham site for 18 months, which will provide capacity for vaccine in bulk product form to be converted into individual doses capable of roll out via a mass vaccination programme.  

      II.1.6) Information about lots
         This contract is divided into lots: No
            
      II.1.7) Total value of the procurement (excluding VAT)
          Value: 50,000,000
                  
         Currency:GBP            

   II.2) Description

      II.2.2) Additional CPV code(s):
            33650000 - General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents.


      II.2.3) Place of performance
      Nuts code:
      UK - UNITED KINGDOM
   
      Main site or place of performance:
      UNITED KINGDOM
             

      II.2.4) Description of the procurement: The reservation of fill & finish manufacturing capacity at C P Pharmaceutical’s Wrexham site for 18 months, which will provide capacity for vaccine in bulk product form to be converted into individual doses capable of roll out via a mass vaccination programme.  

      II.2.5) Award criteria:
                  
      Price - Weighting: 10
            

      II.2.11) Information about options
         Options: No
         

      II.2.13) Information about European Union funds
         The procurement is related to a project and/or programme financed by European Union funds: No
         

      II.2.14) Additional information: Not Provided


Section IV: Procedure

IV.1) Description

   IV.1.1)Type of procedure: Award of a contract without prior publication of a call for competition in the Official Journal of the European Union in the cases listed below (please complete Annex D1)


   IV.1.3) Information about a framework agreement or a dynamic purchasing system
      The procurement involves the establishment of a framework agreement: No       
      

   IV.1.6) Information about electronic auction
      An electronic auction has been used: No

   IV.1.8) Information about the Government Procurement Agreement (GPA)
      The procurement is covered by the Government Procurement Agreement: Yes

IV.2) Administrative information

   IV.2.1) Previous publication concerning this procedure
       Not Provided
   

   IV.2.9) Information about termination of call for competition in the form of a prior information notice
      The contracting authority will not award any further contracts based on the above prior information notice: No

Section V: Award of contract

Award Of Contract (No.1)

   Contract No: TRN: 2526/07/2020    
   Lot Number: Not Provided    
   Title: Not Provided

   A contract/lot is awarded: Yes


   V.2) Award of contract

      V.2.1) Date of conclusion of the contract: 31/07/2020

      V.2.2) Information about tenders
         Number of tenders received: 1
         Number of tenders received from SMEs: Not Provided          
         Number of tenders received from tenderers from other EU Member States: Not Provided          
         Number of tenders received from tenderers from non-EU Member States: Not Provided          
         Number of tenders received by electronic means: Not Provided

      V.2.3) Name and address of the contractor

      The contract has been awarded to a group of economic operators: No
         
         Contractor (No.1)
             C P Pharmaceuticals Limited, 00482106
             Ash Road (North), Wrexham Industrial Estate, Wrexham, LL13 9UF, United Kingdom
             NUTS Code: UK
            The contractor is an SME: No

      V.2.4) Information on value of the contract/lot (excluding VAT)
         Initial estimated total value of the contract/lot: 50,000,000          
         Total value of the contract/lot: 50,000,000
         Currency: GBP

      V.2.5) Information about subcontracting
         The contract is likely to be subcontracted: No
         
Section VI: Complementary information

   VI.3) Additional information: This contract was directly awarded according to Regulation 32(2)(c) - Extreme Urgency of the PCR 2015.

Extreme urgency brought about by events unforeseeable for the contracting authority, and in accordance with the strict conditions stated in the directive, in relation to Covid-19, as per PPN 01/20 March 20.
To view this notice, please click here:
https://www.delta-esourcing.com/delta/viewNotice.html?noticeId=524346000

   VI.4) Procedures for review

      VI.4.1) Review body
          Department of Business, Energy & Industrial Strategy
          1 Victoria Street, London, SW1H 0ET, United Kingdom

      VI.4.3) Review procedure
         Precise information on deadline(s) for review procedures: Not Provided

      VI.4.4) Service from which information about the review procedure may be obtained
         Not Provided

   VI.5) Date of dispatch of this notice: 10/09/2020




ANNEX D

   1. Justification for the choice of the negotiated procedure without prior publication of a call for competition in accordance with Article 32 of Directive 2014/24/EU

      No tenders or no suitable tenders/requests to participate in response to: Not Provided

      The products involved are manufactured purely for the purpose of research, experiment, study or development under the conditions stated in the directive (for supplies only): No       
      
      The works, supplies or services can be provided only by a particular economic operator for the following reason: No

      Extreme urgency brought about by events unforeseeable for the contracting authority and in accordance with the strict conditions stated in the directive: Yes

      Additional deliveries by the original supplier ordered under the strict conditions stated in the directive: No

      
      
      Procurement of supplies quoted and purchased on a commodity market: No

      Purchase of supplies or services on particularly advantageous terms: No


   3. Explanation
          Extreme urgency brought about by events unforeseeable for the contracting authority, and in accordance with the strict conditions stated in the directive, in relation to Covid-19, as per PPN 01/20 March 20.